26
|
Ortega-Albás JJ, López R, Martínez A, Carratalá S, Echeverria I, Ortega P. Kleine-Levin syndrome, GABA, and glutamate. J Clin Sleep Med 2021; 17:609-610. [PMID: 33283755 DOI: 10.5664/jcsm.9058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
27
|
Rodríguez P, Graña S, Alvarez-León EE, Battaglini M, Darias FJ, Hernán MA, López R, Llaneza P, Martín MC, Ramirez-Rubio O, Romaní A, Suárez-Rodríguez B, Sánchez-Monedero J, Arenas A, Lacasa L. A population-based controlled experiment assessing the epidemiological impact of digital contact tracing. Nat Commun 2021; 12:587. [PMID: 33500407 PMCID: PMC7838392 DOI: 10.1038/s41467-020-20817-6] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 12/08/2020] [Indexed: 11/08/2022] Open
Abstract
While Digital contact tracing (DCT) has been argued to be a valuable complement to manual tracing in the containment of COVID-19, no empirical evidence of its effectiveness is available to date. Here, we report the results of a 4-week population-based controlled experiment that took place in La Gomera (Canary Islands, Spain) between June and July 2020, where we assessed the epidemiological impact of the Spanish DCT app Radar Covid. After a substantial communication campaign, we estimate that at least 33% of the population adopted the technology and further showed relatively high adherence and compliance as well as a quick turnaround time. The app detects about 6.3 close-contacts per primary simulated infection, a significant percentage being contacts with strangers, although the spontaneous follow-up rate of these notified cases is low. Overall, these results provide experimental evidence of the potential usefulness of DCT during an epidemic outbreak in a real population.
Collapse
|
28
|
Escribano-Subias P, López R, Almenar L, Lázaro M, Forn I, Torrent A, Blanco I, Barberà JA, Almenar L, Dobaño JMA, Baloira A, Barbado J, Diaz PB, Blanco I, Blanquer D, Ruiz AJB, Cadenas S, Casado I, Chamorro C, Cifrian JM, Cremer D, Delgado E, Delgado JL, Domingo JA, Escribano P, Arangüena LG, Muñoz JPG, Iturbe D, Lara A, Lázaro M, Meseguer ML, López R, Madroñero A, Marín A, Ferragut LM, Escobar EM, Núñez A, de Saracho y Bobo JO, Peralta CA, Peñate GP, Amigó JP, Rodriguez C, Roig V, Rueda X, Sala E, Simón RS. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. BMC Pulm Med 2020; 20:154. [PMID: 32487059 PMCID: PMC7265251 DOI: 10.1186/s12890-020-01197-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Accepted: 05/22/2020] [Indexed: 12/01/2022] Open
Abstract
Background Macitentan is a dual endothelin receptor antagonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH). We evaluated the change over time in REVEAL risk score in incident and prevalent patients receiving macitentan for the first time. Methods Retrospective, observational study including adult patients with idiopathic/heritable PAH or PAH associated with connective tissue disorders or congenital heart disease treated with macitentan for ≥6-month follow-up in Spain. The REVEAL risk score and risk strata were computed at the start of macitentan and after ≥6-month in patients with ≥7 out of 12 valid REVEAL components. Results Overall, 81 patients (57 for the REVEAL score) were analysed, 77.8% women. The mean age was 57.2 years and 50.6% of patients had idiopathic/heritable PAH. Prevalent patients were 59.3 and 40.7% were incident. Main therapies for PAH included macitentan monotherapy (42.0%) and macitentan in combination with phosphodiesterase type 5 inhibitor (44.4%). With a median time of macitentan treatment of 10.5 months, the mean REVEAL score was 8.7 points at baseline and was 7.2 points after ≥6-month follow-up. The mean change (95% CI) in REVEAL risk score was − 1.4 (− 2.0, − 0.9) points (p < 0.0001), being − 1.8 (− 3.0, − 0.7) points (p = 0.0040) and − 1.2 (− 1.8, − 0.5) points (p = 0.0010), in incident and prevalent patients, respectively. The reduction was also significant by risk stratum (36.8% of patients in the high-very high risk strata at baseline versus 14.0% after ≥6-month, p < 0.05) and therapy group. The REVEAL components that significantly improved were WHO functional class (FC) (63.9% FC III at macitentan initiation and 23.6% after ≥6-month, p < 0.0001), 6-min walk test (mean change: 41.8 m, p < 0.01), brain natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) (mean change of − 157.6 pg/mL and − 530.0 pg/mL, respectively, p < 0.05 both), and pulmonary vascular resistance (PVR) (mean change: − 3.4 WU, p < 0.01). Conclusions In this study, treatment with macitentan improved the REVEAL risk strata and score in both incident and prevalent PAH patients, and in all patients regardless of the therapy strategy. Macitentan significantly improved some of REVEAL components including WHO FC, BNP/NT-proBNP, PVR, and 6-min walk test after at least 6-month follow-up.
Collapse
|
29
|
Aab A, Abreu P, Aglietta M, Albury JM, Allekotte I, Almela A, Alvarez Castillo J, Alvarez-Muñiz J, Alves Batista R, Anastasi GA, Anchordoqui L, Andrada B, Andringa S, Aramo C, Araújo Ferreira PR, Asorey H, Assis P, Avila G, Badescu AM, Bakalova A, Balaceanu A, Barbato F, Barreira Luz RJ, Becker KH, Bellido JA, Berat C, Bertaina ME, Bertou X, Biermann PL, Bister T, Biteau J, Blanco A, Blazek J, Bleve C, Boháčová M, Boncioli D, Bonifazi C, Bonneau Arbeletche L, Borodai N, Botti AM, Brack J, Bretz T, Briechle FL, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora KS, Caccianiga L, Calcagni L, Cancio A, Canfora F, Caracas I, Carceller JM, Caruso R, Castellina A, Catalani F, Cataldi G, Cazon L, Cerda M, Chinellato JA, Choi K, Chudoba J, Chytka L, Clay RW, Cobos Cerutti AC, Colalillo R, Coleman A, Coluccia MR, Conceição R, Condorelli A, Consolati G, Contreras F, Convenga F, Covault CE, Dasso S, Daumiller K, Dawson BR, Day JA, de Almeida RM, de Jesús J, de Jong SJ, De Mauro G, de Mello Neto JRT, De Mitri I, de Oliveira J, de Oliveira Franco D, de Souza V, De Vito E, Debatin J, Del Río M, Deligny O, Dembinski H, Dhital N, Di Giulio C, Di Matteo A, Díaz Castro ML, Dobrigkeit C, D'Olivo JC, Dorosti Q, Dos Anjos RC, Dova MT, Ebr J, Engel R, Epicoco I, Erdmann M, Escobar CO, Etchegoyen A, Falcke H, Farmer J, Farrar G, Fauth AC, Fazzini N, Feldbusch F, Fenu F, Fick B, Figueira JM, Filipčič A, Fodran T, Freire MM, Fujii T, Fuster A, Galea C, Galelli C, García B, Garcia Vegas AL, Gemmeke H, Gesualdi F, Gherghel-Lascu A, Ghia PL, Giaccari U, Giammarchi M, Giller M, Glombitza J, Gobbi F, Gollan F, Golup G, Gómez Berisso M, Gómez Vitale PF, Gongora JP, González N, Goos I, Góra D, Gorgi A, Gottowik M, Grubb TD, Guarino F, Guedes GP, Guido E, Hahn S, Halliday R, Hampel MR, Hansen P, Harari D, Harvey VM, Haungs A, Hebbeker T, Heck D, Hill GC, Hojvat C, Hörandel JR, Horvath P, Hrabovský M, Huege T, Hulsman J, Insolia A, Isar PG, Johnsen JA, Jurysek J, Kääpä A, Kampert KH, Keilhauer B, Kemp J, Klages HO, Kleifges M, Kleinfeller J, Köpke M, Kukec Mezek G, Lago BL, LaHurd D, Lang RG, Leigui de Oliveira MA, Lenok V, Letessier-Selvon A, Lhenry-Yvon I, Lo Presti D, Lopes L, López R, Lorek R, Luce Q, Lucero A, Machado Payeras A, Malacari M, Mancarella G, Mandat D, Manning BC, Manshanden J, Mantsch P, Marafico S, Mariazzi AG, Mariş IC, Marsella G, Martello D, Martinez H, Martínez Bravo O, Mastrodicasa M, Mathes HJ, Matthews J, Matthiae G, Mayotte E, Mazur PO, Medina-Tanco G, Melo D, Menshikov A, Merenda KD, Michal S, Micheletti MI, Miramonti L, Mockler D, Mollerach S, Montanet F, Morello C, Mostafá M, Müller AL, Muller MA, Mulrey K, Mussa R, Muzio M, Namasaka WM, Nellen L, Nguyen PH, Niculescu-Oglinzanu M, Niechciol M, Nitz D, Nosek D, Novotny V, Nožka L, Nucita A, Núñez LA, Palatka M, Pallotta J, Panetta MP, Papenbreer P, Parente G, Parra A, Pech M, Pedreira F, Pȩkala J, Pelayo R, Peña-Rodriguez J, Perez Armand J, Perlin M, Perrone L, Peters C, Petrera S, Pierog T, Pimenta M, Pirronello V, Platino M, Pont B, Pothast M, Privitera P, Prouza M, Puyleart A, Querchfeld S, Rautenberg J, Ravignani D, Reininghaus M, Ridky J, Riehn F, Risse M, Ristori P, Rizi V, Rodrigues de Carvalho W, Rodriguez Fernandez G, Rodriguez Rojo J, Roncoroni MJ, Roth M, Roulet E, Rovero AC, Ruehl P, Saffi SJ, Saftoiu A, Salamida F, Salazar H, Salina G, Sanabria Gomez JD, Sánchez F, Santos EM, Santos E, Sarazin F, Sarmento R, Sarmiento-Cano C, Sato R, Savina P, Schäfer C, Scherini V, Schieler H, Schimassek M, Schimp M, Schlüter F, Schmidt D, Scholten O, Schovánek P, Schröder FG, Schröder S, Schulz A, Sciutto SJ, Scornavacche M, Shellard RC, Sigl G, Silli G, Sima O, Šmída R, Sommers P, Soriano JF, Souchard J, Squartini R, Stadelmaier M, Stanca D, Stanič S, Stasielak J, Stassi P, Streich A, Suárez-Durán M, Sudholz T, Suomijärvi T, Supanitsky AD, Šupík J, Szadkowski Z, Taboada A, Tapia A, Timmermans C, Tkachenko O, Tobiska P, Todero Peixoto CJ, Tomé B, Torralba Elipe G, Travaini A, Travnicek P, Trimarelli C, Trini M, Tueros M, Ulrich R, Unger M, Urban M, Vaclavek L, Vacula M, Valdés Galicia JF, Valiño I, Valore L, van Vliet A, Varela E, Vargas Cárdenas B, Vásquez-Ramírez A, Veberič D, Ventura C, Vergara Quispe ID, Verzi V, Vicha J, Villaseñor L, Vink J, Vorobiov S, Wahlberg H, Watson AA, Weber M, Weindl A, Wiencke L, Wilczyński H, Winchen T, Wirtz M, Wittkowski D, Wundheiler B, Yushkov A, Zapparrata O, Zas E, Zavrtanik D, Zavrtanik M, Zehrer L, Zepeda A, Ziolkowski M, Zuccarello F. Features of the Energy Spectrum of Cosmic Rays above 2.5×10^{18} eV Using the Pierre Auger Observatory. PHYSICAL REVIEW LETTERS 2020; 125:121106. [PMID: 33016715 DOI: 10.1103/physrevlett.125.121106] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Accepted: 07/31/2020] [Indexed: 06/11/2023]
Abstract
We report a measurement of the energy spectrum of cosmic rays above 2.5×10^{18} eV based on 215 030 events. New results are presented: at about 1.3×10^{19} eV, the spectral index changes from 2.51±0.03(stat)±0.05(syst) to 3.05±0.05(stat)±0.10(syst), evolving to 5.1±0.3(stat)±0.1(syst) beyond 5×10^{19} eV, while no significant dependence of spectral features on the declination is seen in the accessible range. These features of the spectrum can be reproduced in models with energy-dependent mass composition. The energy density in cosmic rays above 5×10^{18} eV is [5.66±0.03(stat)±1.40(syst)]×10^{53} erg Mpc^{-3}.
Collapse
|
30
|
Juliao-Baños F, Puentes F, López R, Saffon MA, Reyes G, Parra V, Galiano MT, Barraza M, Molano J, Álvarez E, Corrales R, Vargas LE, Gil F, Álvarez P, Limas L, Prieto R, Yance P, Díaz F, Bareño J. Characterization of inflammatory bowel disease in Colombia: Results of a national register. REVISTA DE GASTROENTEROLOGÍA DE MÉXICO 2020; 86:153-162. [PMID: 32723624 DOI: 10.1016/j.rgmx.2020.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2020] [Revised: 04/29/2020] [Accepted: 05/14/2020] [Indexed: 02/07/2023]
Abstract
AIM To determine the clinical, sociodemographic, and treatment characteristics of inflammatory bowel disease (IBD) in a Colombian population register. METHODS A descriptive, analytic, observational, cross-sectional, multicenter study on patients with IBD from 17 hospital centers in 9 Colombian cities was conducted. RESULTS A total of 2,291 patients with IBD were documented, 1,813 (79.1%) of whom presented with ulcerative colitis (UC), 456 (19.9%) with Crohn's disease (CD), and 22 with IBD unclassified (0.9%). The UC/CD ratio was 3.9:1. A total of 18.5% of the patients with UC and 47.3% with CD received biologic therapy. Patients with extensive UC had greater biologic therapy use (OR = 2.78, 95% CI: 2.10-3.65, p = 0.000), a higher surgery rate (OR = 5.4, 95% CI: 3.5-8.3, p = 0.000), and greater frequency of hospitalization (OR = 4.34, 95% CI: 3.47-5.44, p = 0.000). Patients with severe UC had greater biologic therapy use (OR = 5.04, 95% CI: 3.75-6.78, p = 0.000), a higher surgery rate (OR = 8.64, 95% CI: 5.4-13.78, p = 0.000), and greater frequency of hospitalization (OR = 28.45, 95% CI: 19.9-40.7, p = 0.000). CD patients with inflammatory disease behavior (B1) presented with a lower frequency of hospitalization (OR = 0.12, 95% CI: 0.07-0.19, p = 0.000), a lower surgery rate (OR = 0.08, 95% CI: 0.043-0.15, p = 0.000), and less biologic therapy use (OR = 0.26, 95% CI: 0.17-0.41, p = 0.000). CONCLUSION In Colombia, there is a predominance of UC over CD (3.9:1), as occurs in other Latin American countries. Patients with extensive UC, severe UC, or CD with noninflammatory disease behavior (B2, B3) have a worse prognosis.
Collapse
|
31
|
Targa A, Dakterzada F, Benítez ID, de Gonzalo-Calvo D, Moncusí-Moix A, López R, Pujol M, Arias A, de Batlle J, Sánchez-de-la-Torre M, Barbé F, Piñol-Ripoll G. Circulating MicroRNA Profile Associated with Obstructive Sleep Apnea in Alzheimer's Disease. Mol Neurobiol 2020; 57:4363-4372. [PMID: 32720075 DOI: 10.1007/s12035-020-02031-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Accepted: 07/22/2020] [Indexed: 11/29/2022]
Abstract
The diagnosis of obstructive sleep apnea (OSA) in Alzheimer's disease (AD) by polysomnography (PSG) is challenging due to the required collaboration of the patients. In addition, screening questionnaires have demonstrated limited usefulness with this subpopulation. Considering this, we investigated the circulating microRNA (miRNA) profile associated with OSA in AD patients. This study included a carefully selected cohort of females with mild-moderate AD confirmed by biological evaluation (n = 29). The individuals were submitted to one-night PSG to diagnose OSA (apnea-hypopnea index ≥ 15/h) and the blood was collected in the following morning. The plasma miRNA profile was evaluated using RT-qPCR. The patients had a mean (SD) age of 75.8 (5.99) years old with a body mass index of 28.6 (3.83) kg m-2. We observed a subset of 15 miRNAs differentially expressed between OSA and non-OSA patients, of which 10 were significantly correlated with the severity of OSA. Based on this, we built a prediction model that generated an AUC (95% CI) of 0.95 (0.88-1.00) including 5 of the differentially expressed miRNAs that correlated with OSA severity: miR-26a-5p, miR-30a-3p, miR-374a-5p, miR-377-3p, and miR-545-3p. Our preliminary results suggest a plasma miRNA signature associated with the presence of OSA in AD patients. Further studies will be necessary to validate these findings.
Collapse
|
32
|
Santos F, Urbina A, Abad J, López R, Toledo C, Fernández Romero AJ. Environmental and economical assessment for a sustainable Zn/air battery. CHEMOSPHERE 2020; 250:126273. [PMID: 32120147 DOI: 10.1016/j.chemosphere.2020.126273] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Revised: 02/10/2020] [Accepted: 02/17/2020] [Indexed: 06/10/2023]
Abstract
Metal/Air batteries are being developed and soon could become competitive with other battery technologies already in the market, such as Li-ion battery. The main problem to be addressed is the cyclability, although some progress has been recently achieved. A Life Cycle Assessment (LCA) of the manufacturing process of a Zn/Air battery is presented in this article, including raw extraction and process of materials and battery assembly at laboratory scale (cradle to gate approach). The results indicate that Zn/Air battery can be fabricated with low environmental impacts in most categories and only four deserve attention (still being low impacts), such as Human Toxicity (cancer and non-cancer), Freshwater Ecotoxicity and Resource Depletion (the later one depending mainly on Zn use, which is not a critical material, but has a strong impact on this category). Cathode fabrication arises as the subassembly with higher impacts, followed by membrane, then anode and finally electrolyte. An economic cost calculation indicates that if cyclability of Zn/Air batteries is achieved, they can become competitive with other technologies already in the market.
Collapse
|
33
|
Naranjo A, Molina A, Sepúlveda C, Torres C, Santana F, Rubiño F, López R, Ojeda S. AB1180 THE EVOLUTION OF AN FLS IN SEARCH OF EXCELLENCE: THE EXPERIENCE OF GRAN CANARIA. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The implementation of an FLS in the Spanish public health system is not an easy task since there are no official plans for the incorporation of personnel dedicated to the unitObjectives:To expose the consolidation and improvement of an FLS after its implementation as well as the problems that have arisen over time.Methods:The health program for secondary fracture prevention was implemented in 2012. Initially worked with the same staff assigned to the Rheumatology service, since 2016 we have a part-time support nurse. Patients are identified from the emergency registry and, more recently, from patients admitted for hip fracture and treated in a monographic osteoporosis clinic. The baseline visit consists of consultation with the nurse, DXA and bone metabolism analytics. Falling patients are referred to a fall prevention school. Most patients are referred to their primary care physician to start a treatment.Results:Of the 2,416 patients attended the baseline visit, 30% were forearm fractures, 27% hip, 20% humerus, 10% spine and 11% other fractures. In comparison to 2012, in 2019 the monthly average of patients has doubled, increased the number of hip and spine fractures, and increased the percentage of captured patients (Table). In spite of consolidating the unit, getting a support nurse for the admitted patients and establishing a solid alliance with primary care, it is pending the involvement of Primary Care Nurses and start first prescription at the hospital.Table.Comparison of the first year with the last year of implementation of our FLS.20122019Mean monthly number of fractures, N2242Type of fracture: forearm/hip/spine, %37/20/628/40/11Captured patients of elegible, %5777Delay in weeks until first visit to FLS, median1412Patient origin: emergency list/inpatient/outpatient, %100/0/059/31/9DXA performed, %10061Referral to fall prevention school, %026Criteria to start a treatment, %6790*Referral to the osteoporosis clinic, %377*We apply the 2019 recommendations of the Spanish Society of RheumatologyConclusion:We present the achievements made by our FLS along 8 years and the difficulties within the Spanish public health system.Disclosure of Interests:Antonio Naranjo Grant/research support from: amgen, Consultant of: UCB, Speakers bureau: AMGEN, Amparo Molina Speakers bureau: AMGEN, STADA, Cristina Sepúlveda: None declared, Candelaria Torres: None declared, Fabiola Santana: None declared, Francisco Rubiño: None declared, Rubén López: None declared, Soledad Ojeda Speakers bureau: AMGEN, LILLY, GEBRO
Collapse
|
34
|
Arnaez J, Herranz-Rubia N, Garcia-Alix A, Diez-Delgado J, Benavente-Fernández I, Tofé I, Jerez A, Hurtado J, Ceballos J, Millán M, Esquivel M, Ruiz C, Baca M, Tapia E, Losada M, Torres E, Pavón A, Jiménez P, Jiménez F, Ventura M, Rite S, González T, Arias R, Balliu P, Lloreda-García J, Alcaráz J, Tapia C, de la Morena A, Centelles I, Güemes I, Estañ J, Alberola A, Aparici S, López R, Beceiro J, García B, Martínez L, González E, Arruza L, Blanco M, Moral M, Arias B, Mar F, Jiménez J, Romera G, Cuñarro A, Muñóz C, Cabañas F, Valverde E, Montero R, Tejedor J, Santana C, Reyes B, Romero S, Orizaola A, Baquero M, Hernández D, Pantoja A, Vega-del-Val C, Castañón L, Gutiérrez E, Benito M, Caserío S, Arca G, García M, López-Vílchez M, Castells L, Domingo M, Coroleu W, Boix H, Porta R, García-Alix A, Martínez-Nadal S, Jiménez E, Sole E, Albújar M, Fernández E, Barrio A, Piñán E, Avila-Alvarez A, Vázquez M, Balado N, Crespo P, Couce M, Concheiro-Guisán A, Esteban I, Lavilla A, Alzina V, Aguirre A, Loureiro B, Echániz I, Elorza M, Euba A. Atención integral del neonato con encefalopatía hipóxico-isquémica en España. An Pediatr (Barc) 2020; 92:286-296. [DOI: 10.1016/j.anpedi.2019.05.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 05/22/2019] [Accepted: 05/24/2019] [Indexed: 10/26/2022] Open
|
35
|
Couto J, Pontes Dos Santos L, Marques Mendes E, Brito A, López R, Santos C. Epicardial fat necrosis: A rare and benign cause of chest pain. Rev Port Cardiol 2020; 39:113-114. [PMID: 32273048 DOI: 10.1016/j.repc.2019.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2018] [Revised: 01/08/2019] [Accepted: 03/10/2019] [Indexed: 10/24/2022] Open
|
36
|
Jorge C, Cetó M, Arias A, Blasco E, Gil MP, López R, Dakterzada F, Purroy F, Piñol-Ripoll G. Level of understanding of Alzheimer disease among caregivers and the general population. NEUROLOGÍA (ENGLISH EDITION) 2020; 36:426-432. [PMID: 34238525 DOI: 10.1016/j.nrleng.2018.03.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 03/01/2018] [Indexed: 11/15/2022] Open
Abstract
INTRODUCTION Understanding of Alzheimer disease (AD) is fundamental for early diagnosis and to reduce caregiver burden. The objective of this study is to evaluate the degree of understanding of AD among informal caregivers and different segments of the general population through the Alzheimer's Disease Knowledge Scale (ADKS). PATIENTS AND METHODS We assessed the knowledge of caregivers in different follow-up periods (less than one year, between 1 and 5 years, and over 5 years since diagnosis) and individuals from the general population. ADKS scores were grouped into different items: life impact, risk factors, symptoms, diagnosis, treatment, disease progression, and caregiving. RESULTS A total of 419 people (215 caregivers and 204 individuals from the general population) were included in the study. No significant differences were found between groups for overall ADKS score (19.1 vs 18.8, P = .9). There is a scarce knowledge of disease risk factors (49.3%) or the care needed (51.2%), while symptoms (78.6%) and course of the disease (77.2%) were the best understood aspects. Older caregiver age was correlated with worse ADKS scores overall and for life impact, symptoms, treatment, and disease progression (P < .05). Time since diagnosis improved caregivers' knowledge of AD symptoms (P = .00) and diagnosis (P = .05). CONCLUSION Assessing the degree of understanding of AD is essential to the development of health education strategies both in the general population and among caregivers.
Collapse
|
37
|
Couto J, Pontes dos Santos L, Marques Mendes E, Brito A, López R, Santos C. Epicardial fat necrosis: A rare and benign cause of chest pain. REVISTA PORTUGUESA DE CARDIOLOGIA (ENGLISH EDITION) 2020. [DOI: 10.1016/j.repce.2020.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
38
|
Aranda E, Polo E, Camps C, Carrato A, Díaz-Rubio E, Guillem V, López R, Antón A. Treatment patterns for metastatic colorectal cancer in Spain. Clin Transl Oncol 2020; 22:1455-1462. [PMID: 31974819 PMCID: PMC7381444 DOI: 10.1007/s12094-019-02279-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 12/19/2019] [Indexed: 11/27/2022]
Abstract
Purpose The primary aim of this retrospective study was to describe the treatment patterns according to the type of treatment received by patients with metastatic colorectal cancer (mCRC) in Spain. Methods This was a retrospective, observational, multicenter study performed by 33 sites throughout Spain that included consecutive patients aged 18 years or older who had received or were receiving treatment for mCRC. Results At the time of inclusion, of the 873 evaluable patients, 507 (58%) had received two lines, 235 (27%) had received three lines, 106 (12%) had received four lines, and the remaining patients had received up to ten lines. The most frequent chemotherapy schemes were the FOLFOX or CAPOX regimens (66%) for first-line treatment, FOLFOX, CAPOX or FOLFIRI (70%) for second-line treatment, and FOLFOX, FOLFIRI or other fluoropyrimidine-based regimens for third- and fourth-line (over 60%) treatment. Sixty percent of patients received targeted therapy as part of their first-line treatment, and this proportion increased up to approximately 70% of patients as part of the second-line of treatment. A relevant proportion of patients were treated with unknown KRAS, and especially the BRAF, mutation statuses. Conclusions This study reveals inconsistencies regarding adherence to the recommendations of the ESMO guidelines for the management of mCRC in Spain. Improved adherence to the standard practice described in such guidelines for the determination of RAS and BRAF mutation statuses and the use of targeted therapies in first-line treatment should be considered to guarantee that patients can benefit from the best therapeutic approaches available.
Collapse
|
39
|
Esser M, Lindner A, López R, Muriel M, Boffi F. Factors influencing resting heart rate in endurance racehorses. PFERDEHEILKUNDE 2020. [DOI: 10.21836/pem20200605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Celma A, López R, Roche S, Planas J, Regis L, Placer J, Borque A, Esteban L, de Torres I, Morote J. Are targeted prostate biopsies ready to replace systematic prostate biopsies? Actas Urol Esp 2019; 43:573-578. [PMID: 31679807 DOI: 10.1016/j.acuro.2018.06.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Revised: 06/07/2018] [Accepted: 06/09/2018] [Indexed: 12/27/2022]
Abstract
OBJECTIVES To evaluate the efficacy and efficiency of systematic prostatic biopsy (SPB) and cognitive fusion PB (CFPB) to diagnose prostate cancer (PCa) and significant PCa (SPCa), and to analyse if CFPB could safely replace SPB. MATERIAL AND METHODS A cohort of 314 consecutive men having PI-RADS ≥2 in a pre-biopsy 3T mp-MRI were prospectively subjected to trans-rectal ultrasound CFPB (two cores per suspicious area until a maximum of three areas) and a 12 peripheral core SPB. SPCa was considered when the WHO grade was higher than 2 (Gleason 4+3 or higher). RESULTS PCa was diagnosed in 133 patients (42.4%), being 83 (62.4%) SPCa. SPB detected PCa in 114 men (85.7%) while CFPB in 103 (77.4%), P<.001. SPB detected SPCa in 64 men (77.1%) while CFPB in 71 (85.5%), P<.001. In 52 of the 81 men (64.2%) SPCa was detected in SPB and CFPB. In 19 men SPCa was only detected in CFPB (23.5%) while in 10, it was only detected in SPB (12.3%). 33.1 cores were needed to diagnose one PCa in SPB while 8.5 in CFPB, P<.001. 58.9 cores were needed to diagnose one SPCa in SPB, while 12.4 in CFPB, P<.001. CONCLUSIONS CFPB are more effective and also more efficient than SPBs in detecting SPCa. However, CFPBs still can't safely replace SPBs because they are not able to detect up to 15% of SPCa.
Collapse
|
41
|
Aab A, Abreu P, Aglietta M, Albuquerque I, Albury J, Allekotte I, Almela A, Alvarez Castillo J, Alvarez-Muñiz J, Anastasi G, Anchordoqui L, Andrada B, Andringa S, Aramo C, Asorey H, Assis P, Avila G, Badescu A, Bakalova A, Balaceanu A, Barbato F, Barreira Luz R, Baur S, Becker K, Bellido J, Berat C, Bertaina M, Bertou X, Biermann P, Biteau J, Blaess S, Blanco A, Blazek J, Bleve C, Boháčová M, Boncioli D, Bonifazi C, Borodai N, Botti A, Brack J, Bretz T, Bridgeman A, Briechle F, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora K, Caccianiga L, Calcagni L, Cancio A, Canfora F, Carceller J, Caruso R, Castellina A, Catalani F, Cataldi G, Cazon L, Cerda M, Chinellato J, Chudoba J, Chytka L, Clay R, Cobos Cerutti A, Colalillo R, Coleman A, Coluccia M, Conceição R, Condorelli A, Consolati G, Contreras F, Convenga F, Cooper M, Coutu S, Covault C, Daniel B, Dasso S, Daumiller K, Dawson B, Day J, de Almeida R, de Jong S, De Mauro G, de Mello Neto J, De Mitri I, de Oliveira J, de Oliveira Salles F, de Souza V, Debatin J, del Río M, Deligny O, Dhital N, Díaz Castro M, Diogo F, Dobrigkeit C, D’Olivo J, Dorosti Q, dos Anjos R, Dova M, Dundovic A, Ebr J, Engel R, Erdmann M, Escobar C, Etchegoyen A, Falcke H, Farmer J, Farrar G, Fauth A, Fazzini N, Feldbusch F, Fenu F, Ferreyro L, Figueira J, Filipčič A, Freire M, Fujii T, Fuster A, García B, Gemmeke H, Gherghel-Lascu A, Ghia P, Giaccari U, Giammarchi M, Giller M, Głas D, Glombitza J, Gobbi F, Golup G, Gómez Berisso M, Gómez Vitale P, Gongora J, González N, Goos I, Góra D, Gorgi A, Gottowik M, Grubb T, Guarino F, Guedes G, Guido E, Halliday R, Hampel M, Hansen P, Harari D, Harrison T, Harvey V, Haungs A, Hebbeker T, Heck D, Heimann P, Hill G, Hojvat C, Holt E, Homola P, Hörandel J, Horvath P, Hrabovský M, Huege T, Hulsman J, Insolia A, Isar P, Jandt I, Johnsen J, Josebachuili M, Jurysek J, Kääpä A, Kampert K, Keilhauer B, Kemmerich N, Kemp J, Klages H, Kleifges M, Kleinfeller J, Krause R, Kuempel D, Kukec Mezek G, Kuotb Awad A, Lago B, LaHurd D, Lang R, Legumina R, Leigui de Oliveira M, Lenok V, Letessier-Selvon A, Lhenry-Yvon I, Lippmann O, Lo Presti D, Lopes L, López R, López Casado A, Lorek R, Luce Q, Lucero A, Malacari M, Mancarella G, Mandat D, Manning B, Mantsch P, Mariazzi A, Mariş I, Marsella G, Martello D, Martinez H, Martínez Bravo O, Mastrodicasa M, Mathes H, Mathys S, Matthews J, Matthiae G, Mayotte E, Mazur P, Medina-Tanco G, Melo D, Menshikov A, Merenda KD, Michal S, Micheletti M, Middendorf L, Miramonti L, Mitrica B, Mockler D, Mollerach S, Montanet F, Morello C, Morlino G, Mostafá M, Müller A, Muller M, Müller S, Mussa R, Nellen L, Nguyen P, Niculescu-Oglinzanu M, Niechciol M, Nitz D, Nosek D, Novotny V, Nožka L, Nucita A, Núñez L, Olinto A, Palatka M, Pallotta J, Panetta M, Papenbreer P, Parente G, Parra A, Pech M, Pedreira F, Pȩkala J, Pelayo R, Peña-Rodriguez J, Pereira L, Perlin M, Perrone L, Peters C, Petrera S, Phuntsok J, Pierog T, Pimenta M, Pirronello V, Platino M, Poh J, Pont B, Porowski C, Prado R, Privitera P, Prouza M, Puyleart A, Querchfeld S, Quinn S, Ramos-Pollan R, Rautenberg J, Ravignani D, Reininghaus M, Ridky J, Riehn F, Risse M, Ristori P, Rizi V, Rodrigues de Carvalho W, Rodriguez Rojo J, Roncoroni M, Roth M, Roulet E, Rovero A, Ruehl P, Saffi S, Saftoiu A, Salamida F, Salazar H, Salina G, Sanabria Gomez J, Sánchez F, Santos E, Santos E, Sarazin F, Sarmento R, Sarmiento-Cano C, Sato R, Savina P, Schauer M, Scherini V, Schieler H, Schimassek M, Schimp M, Schlüter F, Schmidt D, Scholten O, Schovánek P, Schröder F, Schröder S, Schumacher J, Sciutto S, Scornavacche M, Shellard R, Sigl G, Silli G, Sima O, Šmída R, Snow G, Sommers P, Soriano J, Souchard J, Squartini R, Stanca D, Stanič S, Stasielak J, Stassi P, Stolpovskiy M, Streich A, Suarez F, Suárez-Durán M, Sudholz T, Suomijärvi T, Supanitsky A, Šupík J, Szadkowski Z, Taboada A, Taborda O, Tapia A, Timmermans C, Todero Peixoto C, Tomé B, Torralba Elipe G, Travaini A, Travnicek P, Trini M, Tueros M, Ulrich R, Unger M, Urban M, Valdés Galicia J, Valiño I, Valore L, van Bodegom P, van den Berg A, van Vliet A, Varela E, Vargas Cárdenas B, Veberič D, Ventura C, Vergara Quispe I, Verzi V, Vicha J, Villaseñor L, Vink J, Vorobiov S, Wahlberg H, Watson A, Weber M, Weindl A, Wiedeński M, Wiencke L, Wilczyński H, Winchen T, Wirtz M, Wittkowski D, Wundheiler B, Yang L, Yushkov A, Zas E, Zavrtanik D, Zavrtanik M, Zehrer L, Zepeda A, Zimmermann B, Ziolkowski M, Zong Z, Zuccarello F. Data-driven estimation of the invisible energy of cosmic ray showers with the Pierre Auger Observatory. Int J Clin Exp Med 2019. [DOI: 10.1103/physrevd.100.082003] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
42
|
Galindo G, Galarza J, García L, Padilla A, Negrete A, López R. Normative Data for Executive Function and Emotion Interaction Assessment in Adolescents from Rural Areas. Arch Clin Neuropsychol 2019. [DOI: 10.1093/arclin/acz029.19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Objective
The present work is part of the ongoing project of examining the validation and standardization of the Executive Functions and Emotion Assessment for Adolescents with Risk Behaviors (EFEAA) test in the rural areas of Northwest Mexico. The objectives of the present study were (1) to examine the effects of age and risk behavior on emotionally interfered working memory ability, measured as performance on the Emotionally Interfered Working Memory Task (EIWMT) section of the EFEAA in a group of healthy adolescents from rural areas; and (2) to use these results to construct normative data that can be used in clinical practice.
Participants and Method
A total of 275 adolescents, 14.1 years old, geographically distributed among northwest Mexico were included in the sample. They were individually assessed using the Montreal Cognitive Assessment, Risk Behavior Questionnaire, including: sexual risk behavior, impulsiveness, drug, alcohol, and tobacco consumption, unhealthy food intake, and physical inactivity; for measuring emotion-cognition interaction we used the EIWMT.
Results
Results of this study present a database supported by factors of risk behavior and working memory, which includes: predictors for conduct disorders, drug use, and delinquency, in addition to correlations between the performance of emotionally interfered working memory and risk behaviors associated to health. Percentile and normal distribution tables were generated, demonstrating that there is a high prevalence of risk behavior in rural areas.
Conclusions
This study demonstrates data related to rural areas in northwest Mexico, a region where adolescents are frequently involved in risk behaviors. Additionally, protective factors are understudied in Mexico-US border cities. Further analyses are needed to find reward delay skills on the studied sample as well as urban area comparisons.
Collapse
|
43
|
Trigo Perez J, Subbiah V, Besse B, Moreno V, López R, Sala M, Ponce S, Fernendez C, Nieto A, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martinez M, Delord J, Awada A, Kristeleit R, Longo F, Sarantopoulos J, Rubio M, Anton A, Wannesson L, Valdivia J, Shappiro G, Villalobos V, Santoro A, D'Arcangelo M, Aparicio L, Paz-Ares L. P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Massuti Sureda B, Sanchez Torres J, Cobo Dols M, Moran Bueno M, Gonzalez-Larriba J, Barneto Aranda I, De Castro Carpeno J, Iglesias L, Muñoz M, López Vivanco G, Isla Casado M, López R, de las Penas Bataller R, Rodriguez Abreu D, Artal-Cortes A, Esteban E, Provencio M, Pereira E, Sanchez-Paya J, Rosell R. BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Aranda Aguilar E, Garcia Foncillas J, Antón A, Camps Herrero C, Carrato Mena A, Constenla Figueiras M, Cruz Hernandez J, Diaz Rubio E, Gascon P, Guillem Porta V, López R, Feyjóo M, Puente J. Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz265.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Redin E, Villalba M, Exposito F, Pajares M, Sainz C, Hervas D, Guruceaga E, Diaz-Lagares A, Cirauqui C, Redrado M, De Andrea C, Jantus E, Camps C, López R, Lahoz A, Montuenga L, Pio R, Sandoval J, Calvo A. P2.03-38 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
47
|
Massuti B, Sanchez J, Cobo M, Moran T, Larriba JG, Barneto I, De Castro Carpeno J, Iglesias L, Muñoz M, López-Vivanco G, Isla D, López R, De Las Penas R, Rodriguez-Abreu D, Artal A, Esteban E, Provencio M, Pereira E, Sanchez-Payá J, Rosell R. MA02.01 Reccurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Alés-Martínez J, Morales S, Fernández Abad M, Sánchez-Rovira P, Salvador Bofill F, Lahuerta A, García-Sáenz J, Garau Llinas I, Díaz Redondo T, Ferrer N, Carañana V, López R, Alonso Soler S, Bermejo B, de la Haba J, Zamora P, Balmana J, López-Miranda E, Cortés J, Llombart Cussac A. Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Pérez C, Mondéjar R, García-Díaz N, Cereceda L, León A, Montes S, Durán Vian C, Pérez Paredes MG, González-Morán A, Alegre de Miguel V, Sanz Anquela JM, Frias J, Limeres MA, González LM, Martín Dávila F, Beltrán M, Mollejo M, Méndez JR, González MA, González García J, López R, Gómez A, Izquierdo F, Ramos R, Camacho C, Rodriguez-Pinilla SM, Martínez N, Vaqué JP, Ortiz-Romero PL, Piris MA. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways. Br J Dermatol 2019; 182:147-155. [PMID: 31049933 DOI: 10.1111/bjd.18098] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/23/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND The malignant mechanisms that control the development of cutaneous T-cell lymphoma (CTCL) are beginning to be identified. Recent evidence suggests that disturbances in specific intracellular signalling pathways, such as RAS-mitogen-activated protein kinase, T-cell receptor (TCR)-phospholipase C gamma 1 (PLCG1)-nuclear factor of activated T cells (NFAT) and Janus kinase (JAK)-signal transducer and activator of transcription (STAT), may play an essential role in the pathogenesis of CTCL. OBJECTIVES To investigate the mechanisms controlling disease development and progression in mycosis fungoides (MF), the most common form of CTCL. METHODS We collected 100 samples that were submitted for diagnosis of, or a second opinion regarding, MF between 2001 and 2018, 80% of which were in the early clinical stages of the disease. Formalin-fixed paraffin-embedded tissues were used for histological review and to measure the expression by immunohistochemistry of surrogate markers of activation of the TCR-PLCG1-NFAT, JAK-STAT and NF-κB pathways. Folliculotropism and large-cell transformation were also examined. RESULTS NFAT and nuclear factor kappa B (NF-κB) markers showed a comparable activation status in early and advanced stages, while STAT3 activation was more frequent in advanced stages and was associated with large-cell transformation. Consistently with this observation, STAT3 activation occurred in parallel with MF progression in two initially MF-negative cases. A significant association of NFAT with NF-κB markers was also found, reflecting a common mechanism of activation in the two pathways. Genomic studies identified nine mutations in seven genes known to play a potential role in tumorigenesis in T-cell leukaemia/lymphoma, including PLCG1, JAK3 and STAT3, which underlies the activation of these key cell-survival pathways. A higher mutational allele frequency was detected in advanced stages. CONCLUSIONS Our results show that STAT3 is activated in advanced cases and is associated with large-cell transformation, while the activation of NFAT and NF-κB is maintained throughout the disease. These findings could have important diagnostic and therapeutic implications. What's already known about this topic? Mycosis fungoides is characterized by a clonal expansion of T cells in the skin. The mechanisms controlling disease development and progression are not fully understood. What does this study add? An association of the nuclear factor of activated T cells and nuclear factor kappa B pathways was found, which could reflect a common mechanism of activation. These pathways were activated in early and advanced stages at the same level. Signal transducer and activator of transcription 3 activation was associated with large-cell transformation and was more frequent in advanced stages. A genomic analysis of cutaneous T-cell lymphoma-associated genes was performed. Nine mutations were detected. What is the translational message? These results could have important implications for the treatment of MF in the near future.
Collapse
|
50
|
Quintero Aldana G, Salgado M, Candamio S, Méndez JC, Jorge M, Reboredo M, Vázquez Tuñas L, Romero C, Covela M, Fernández Montes A, Carmona M, Vidal Insua Y, López R. First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial. Clin Transl Oncol 2019; 22:495-502. [DOI: 10.1007/s12094-019-02151-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Accepted: 05/29/2019] [Indexed: 12/11/2022]
|